हमारा समूह 1000 से अधिक वैज्ञानिक सोसायटी के सहयोग से हर साल संयुक्त राज्य अमेरिका, यूरोप और एशिया में 3000+ वैश्विक सम्मेलन श्रृंखला कार्यक्रम आयोजित करता है और 700+ ओपन एक्सेस जर्नल प्रकाशित करता है जिसमें 50000 से अधिक प्रतिष्ठित व्यक्तित्व, प्रतिष्ठित वैज्ञानिक संपादकीय बोर्ड के सदस्यों के रूप में शामिल होते हैं।
ओपन एक्सेस जर्नल्स को अधिक पाठक और उद्धरण मिल रहे हैं
700 जर्नल और 15,000,000 पाठक प्रत्येक जर्नल को 25,000+ पाठक मिल रहे हैं
Naro Antonino, Billeri Luana, Corpina Flavio, Ferlazzo Marco, Criaco Fabio, Fugazzotto Domenico
Objective: Tracking cognitive impairment in patients with coronavirus disease 2019 (COVID-19) requires objective markers to monitor therapy responses and prognosticate neurological recovery. We sought to assess if quantitative EEG (QEEG) analysis could help identifying peculiar features suggesting COVID-19 related encephalopathy regardless of brain damage related to pulmonary failure.
Methods: A patient, who survived to a severe respiratory failure due to COVID-19 pneumonia, developed a severe neurocognitive syndrome. The patient underwent QEEG monitoring (global coherence, GC) before after one month of intensive cardiopulmonary and motor rehabilitation.
Results: We found a high-frequency strong central-temporal-parietal connectivity at baseline. This was replaced by low-frequency frontal-parietal connectivity. EEG signals and their modifications were unrelated to the former acute respiratory failure.
Conclusion: A decrease of front parietal GC in the upper alpha and beta band in resting state may be a key feature of COVID-19-related encephalopathy. This may depend on a virus-induced brain damage causing loss of connections that are essential to orchestrate the interactions between brain regions at a global level concerning cognitive functions. Significance: Our data suggest that assessing GC seems promising to evidence a frontoparietal connectivity impairment sustaining the COVID-19 neurocognitive syndrome. Once confirmed in larger samples, these QEEG findings may support clinicians in the management and prognosis of COVID-19 patients.